NGM — NGM Biopharmaceuticals Share News
0.000.00%
Last trade - 00:00- $128.53m
- -$15.65m
- $4.42m
Brief: NGM Biopharmaceuticals Inc - On April 3, Board Approved A Restructuring Of Company's Workforce
NGM Biopharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Ngm Bio Provides Business Highlights And Reports Fourth Quarter And Full Year 2022 Financial Results
NGM Biopharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview
Brief: Ngm Biopharmaceuticals Inc- Merck Has Verbally Notified The Company That It Will Not Exercise Its Option To License Ngm621 And Its Related Compounds
Brief: NGM Bio Presents Preliminary Data From Phase 1 Monotherapy Dose Escalation Trial Of Ngm707
Brief: NGM Bio Announces Poster Presentation Featuring Preclinical Characterization Of NGM936 At Upcoming 2022 ASH Annual Meeting
NGM Biopharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
NGM Biopharmaceuticals Inc expected to post a loss of 59 cents a share - Earnings Preview
Apellis Pharma gains as Raymond James raises PT
U.S. RESEARCH ROUNDUP- Domino's Pizza, Juniper Networks, Walmart
U.S. STOCKS ON THE MOVE-Alvotech, Verizon, Lyft, BofA
NGM Biopharmaceuticals hits record low as eye disease drug fails in study
U.S. STOCKS ON THE MOVE-Gold miners, Protera, Sorrento
U.S. STOCKS ON THE MOVE-Bank of America, Archaea, Roblox
Brief: NGM Biopharmaceuticals Expects To Report It Had About $300 Mln Cash, Cash Equivalents & Short-Term Marketable Securities As Of Sept 30
NGM Biopharmaceuticals slumps as eye disease drug fails in study
Brief: Ngm Bio Announces Topline Results From The Catalina Phase 2 Trial Of Ngm621 In Patients With Geographic Atrophy (Ga) Secondary To Age-Related Macular Degeneration
Brief: NGM Bio Presents Updated Preliminary Findings From The Ongoing Phase 1B Dose Escalation Trial Of NGM120